Hamamatsu Photonics has announced U.S. Food and Drug Administration 510(k) clearances for its NanoZoomer S20MD and NanoZoomer S540MD slide-scanner systems, expanding the company’s regulated digital pathology portfolio beyond the previously cleared S360MD. The S20MD is positioned for compact benchtop deployment, while the S540MD is intended for laboratories requiring substantially higher-throughput slide scanning. FDA records show the S20MD received its substantial-equivalence decision on July 15, 2026 and the S540MD followed on July 22, with Hamamatsu publicly announcing the portfolio expansion on September 2.
The clearances are relevant because whole-slide imaging is moving clinical pathology away from a workflow in which diagnosis depends entirely on viewing physical glass slides through a microscope. Whole-slide scanners digitize prepared tissue sections at microscopic resolution, allowing pathologists to review cases on validated displays, share specimens more easily between locations and create digital datasets that can support remote consultation and computational pathology. The FDA classifies both new NanoZoomer systems as Class II whole-slide imaging devices under the pathology product code PSY.
What is the difference between the S20MD, S360MD and S540MD systems?
Hamamatsu is using the three systems to cover laboratories with different volume requirements rather than treating one scanner as appropriate for every pathology operation. The newly cleared S20MD is the compact benchtop option, the S360MD sits within routine laboratory workflows and the S540MD provides the high-throughput configuration. All three are intended to provide a consistent NanoZoomer user experience while allowing laboratories to scale hardware according to workload.
That portfolio strategy matters because pathology departments can differ dramatically in size. A small regional laboratory may need digital capability without dedicating substantial floor space to a high-capacity scanner, while a large academic or reference laboratory may process hundreds or thousands of slides and prioritize automation and throughput. Offering multiple FDA-cleared devices within one ecosystem can make it easier for hospital networks to standardize workflows while using different scanner capacities at different sites.
What does a whole-slide imaging scanner actually do?
Histopathology begins with physical tissue. A biopsy or surgical specimen is processed, embedded, cut into extremely thin sections, mounted on glass and stained so microscopic structures become visible. A whole-slide imaging system scans that entire glass slide at high resolution and creates a digital image that preserves enough detail for a pathologist to review the specimen electronically.
The FDA’s device description characterizes these systems as microscope-slide digital imaging scanners designed for histopathology laboratories, with high-resolution cameras, slide handling, software for image creation and tools that assist pathologists in reviewing and interpreting clinical specimens. The digital image does not change the underlying biological sample, but it changes how that sample can be accessed, moved and analyzed.
Why is FDA clearance important when research laboratories have used digital slide scanners for years?
Using a scanner for research is different from relying on it in a regulated clinical diagnostic workflow. When a pathologist uses a digital image as part of patient diagnosis, the system must provide performance appropriate for clinical use and operate under specified conditions. FDA review therefore addresses whether the new device is substantially equivalent to an appropriate legally marketed predicate for its intended diagnostic role.
Hamamatsu has produced NanoZoomer research systems for more than two decades, but the U.S. clinical market requires device-specific regulatory authorization. The new clearances broaden the range of Hamamatsu hardware that U.S. pathology laboratories can deploy within validated clinical workflows rather than limiting regulated use to one scanner size.
Could digital pathology help address shortages of pathologists?
Potentially, because digitization changes the relationship between specimen location and expert location. A physical glass slide traditionally needs to be viewed wherever the microscope and slide are located or physically transported to another specialist. Once scanned through an appropriate clinical system, cases can be routed through digital infrastructure so that specialists can review them from another workstation or site under validated conditions.
This could be particularly useful for health systems operating several hospitals or for subspecialties where expert pathologists are concentrated in large academic centers. Digital workflow does not create additional pathologists, but it can reduce geographical friction and help laboratories distribute cases according to expertise and workload. The value will depend on networking, storage, displays, information-system integration and institutional validation rather than on scanner clearance alone.
Why does digital pathology matter for AI development?
Artificial-intelligence pathology systems require digital images. A glass slide sitting under a microscope is not directly accessible to an algorithm, while a high-resolution whole-slide image can be processed computationally for tasks such as detecting suspicious regions, quantifying biomarkers, counting cells or supporting tumor grading. Wider use of FDA-cleared clinical scanners therefore creates the digital infrastructure on which computational pathology can build.
That does not mean an AI application automatically becomes authorized because it uses images from an FDA-cleared scanner. Algorithms require their own validation and regulatory pathway depending on intended use, while interoperability between scanners and software can also affect performance. Still, pathology cannot become meaningfully computational at scale unless the underlying tissue slides are first converted into reliable digital data.
How competitive is the U.S. whole-slide imaging market becoming?
Competition is increasing. FDA records show recent whole-slide imaging clearances involving companies including Hamamatsu, Leica Biosystems, Philips and Roche, alongside newer entrants and software-connected pathology platforms. The market is therefore moving from early proof that primary diagnosis can be performed digitally toward competition around throughput, workflow integration, image quality, storage requirements and compatibility with AI tools.
Hamamatsu’s advantage is its ability to offer several scanner capacities within one product family. Whether laboratories choose that portfolio will depend on practical issues including acquisition cost, reliability, service support and integration into existing laboratory-information systems. The new 510(k) decisions give Hamamatsu more hardware options with which to compete as digital pathology moves deeper into routine U.S. clinical practice.
